News and Events

Celebrating CCR Careers: Zhengping Zhuang, M.D., Ph.D.

Zhengping Zhuang, M.D., Ph.D., is a world-renowned expert in experimental pathology, cancer genetics and cancer therapeutics. He has contributed to biotechnological advancements, drug development and clinical translation of his work in tumor biology. After 32 years serving the NCI, he has announced his retirement.

Acute myeloid leukemia. Image credit: iStock

Researchers uncover why a leukemia treatment can cause problems with movement and balance

Ara-C, also known as cytarabine, is the most common chemotherapy to cause cerebellar toxicity. Researchers discovered how the treatment leaves certain neurons with double-strand breaks in their DNA.

Doctor with patient. Image credit: Canva

Clinical trial researching drug therapy for cancers of the female reproductive organs

A clinical trial led by Jung-Min Lee, M.D., Senior Investigator in the Women’s Malignancies Branch, is researching drug therapy for ovarian, endometrial or cervical cancers.

Shioko Kimura, Ph.D., in her CCR lab in 2014.

Celebrating CCR Careers: Shioko Kimura, Ph.D.

Shioko Kimura, Ph.D., is a biochemist who specializes in endocrinology. She studies how certain genes and proteins work in the thyroid gland and the lungs. After almost 40 years at NCI, she has announced her retirement.

Blood from wildtype mice (left) showing blast-like T-ALL cells with characteristic blue nuclear staining; blood from mice in which CHMP5 is deficient in thymocytes (right) showing no evidence of T-ALL cells in the blood.

Protein shown to promote transcription factors that support cancer genes in leukemia

CCR researchers have discovered that the CHMP5 protein promotes transcription factors that initiate and sustain the expression of cancer genes in T-cell acute lymphoblastic leukemia models.

Jim Mitchell in front of a machine and a sign that says X-ray on

Celebrating CCR Careers: James B. Mitchell, Ph.D.

James (Jim) B. Mitchell, Ph.D., is a radiation biologist whose research focuses on evaluation of agents in combination with radiation that either enhance tumor sensitivity or protect normal tissues. After nearly 50 years at the NCI, Mitchell has announced his retirement.